AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03403491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sham application
Description: dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms
Study NCT02694523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo risankizumab administered by subcutaneous (SC) injection
Study NCT02694523 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo for adalimumab
Description: Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
Study NCT04877106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin Phosphate/metformin Hydrochloride Tablets(JANUMET®,50mg/850mg)
Description: The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (JANUMET®, 50mg/850mg)
Study NCT04877106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
Description: The subjects randomly received single oral administration of Sitagliptin Phosphate/metformin Hydrochloride Tablets (50mg/850mg)
Study NCT00495664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titan stent and Taxus-Liberte stent
Study NCT00495664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titan stent and Taxus-Liberte stent
Study NCT01132573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given PO
Study NCT01132573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV
Study NCT01132573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01132573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00633828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased physical education in primary school (daily)
Description: Increased physical education in primary school, 40 minutes per day
Study NCT00713401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecadenoson
Description: Tecadenoson administered intravenously (i.v.)
Study NCT01272661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Curriculum
Description: Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
Study NCT01272661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Curriculum+Breastfeeding Doula
Description: In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
Study NCT00708448 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.
Study NCT00708448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg/day
Study NCT00708448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg q 21 days
Study NCT03463460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03463460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03463460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT01272661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Curriculum +Father Support
Description: In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
Study NCT01058265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative
Description: Integrative Medicine medical evaluation.
Study NCT04418505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vielight RX Plus
Description: The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
Study NCT03487510 — intervention group
Intervention type: OTHER
Intervention: NO interventions apply
Description: does not apply
Study NCT01058265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard general medical evaluation.
Study NCT03505008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Route of Administration: Subcutaneous
Study NCT01690260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Morphogenetic Protein 2
Description: 12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
Study NCT01690260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone graft
Description: Autologous bone graft in connection with bone docking operation.
Study NCT02260674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 10 milligram (mg)
Description: Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
Study NCT03405753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia, washout and then placebo
Description: Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
Study NCT02260674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911, 50 mg
Description: Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
Study NCT02260674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
Study NCT04585373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-taping with conventional therapy 24 hours
Description: standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa.
Study NCT04585373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-taping with conventional therapy 48 hours
Description: standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa.
Study NCT04585373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-taping with conventional therapy 72 hours
Description: standardized therapeutic KT application along with conventional therapy (hot pack ,strengthening and stretching exercises) quadriceps tapping: In the supine position, the Y shape tape will be applied from the middle of the thigh to the upper edge of the patella, Then, the tape will anchored to the inner and outer aspect of the patella with 25% muscle tension and the distal end of the strips are positioned on the tibial tubercle without any tension.~McConnell Patellar tapping technique:~The patient will be positioned in long sitting position; affected knee joint exposed. As per McConnell patellar taping technique, tape will applied from superior and lateral patellar borders, maximally pulling it medially. A second strip can be used for reinforcement, but it should not cover the popliteal fossa.
Study NCT04774120 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Propofol will be started at a rate of 15-20 mg/kg/hr in patients >65 years and 20-25 mg/kg/hr in younger patients (\<65 years) until a suppression rate (SR) is achieved. If not, can be increased by 5 mg/kg/hr every 5 minutes up to 25 mg/kg/hr in the elderly group and 30 mg/kg/hr in the younger group or after 15 minutes have passed. When the SR appears, propofol infusion will be stopped. Then restarted at half of the initial rate. Maintenance of anesthesia will be guided by Sedline Monitor to maintain an alpha band present in the spectrogram and SEF95 between 8-12 Hz. BIS monitor will be covered. Both EEG signals (Sedline and BIS) will be registered simultaneously until the patient's extubation.
Study NCT02331875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2201
Description: The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
Study NCT02331875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Surgery
Description: After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
Study NCT02331875 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Postsurgical Adjuvant Therapy
Description: After the standard surgery, according to standard recommendations in the relevant country
Study NCT00414921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Clonidine is FDA-approved for the treatment of hypertension in adults
Study NCT00414921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate
Description: Methylphenidate is known to safely and effectively treat many ADHD symptoms.
Study NCT00414921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive substance
Study NCT03408002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro
Study NCT04115644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
Study NCT04115644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marcaine (placebo)
Description: Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
Study NCT04115644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine (placebo)
Description: Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
Study NCT04115644 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Marcaine (placebo)
Description: Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
Study NCT03405753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aronia, washout and then placebo
Description: Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
Study NCT03405753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, washout and then aronia
Description: Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
Study NCT03405753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, washout and then aronia
Description: Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
Study NCT02322931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-operative C-arm CT imaging
Description: 1. Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.~2. Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.~3. One Cine loop C-arm scan in the sagittal plane while retracting the probe.~4. One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down).
Study NCT04115644 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Kenalog
Description: Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
Study NCT00236197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Study NCT00236197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Study NCT04131894 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autogenous dentin graft
Study NCT04131894 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich fibrin (PRF)
Study NCT05151419 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bronchoscpe
Description: bronchoscopic biopsy from lung mass using cryobiopsy and forceps
Study NCT02577575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
Study NCT02577575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study NCT01407887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)
Description: The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
Study NCT02496156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Clinical Practice
Description: Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
Study NCT03843112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivag Plus
Description: Contains two lactobacilli strains; l. gasseri and l. rhamnosus
Study NCT03843112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Vaginal supplements
Study NCT02349022 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [89Zr]Df-IAB2M
Study NCT00967148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin
Description: The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
Study NCT02343081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Study NCT02343081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT00967148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
Study NCT04516187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: signs and symptoms, blood tests
Description: signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Million Hearts ABCS 6 Months
Description: The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Million Hearts ABCS 9 Months
Description: The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Million Hearts ABCS 12 Months
Description: The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Million Hearts ABCS 15 Months
Description: The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Regimen 9 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Regimen 12 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Regimen 15 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Regimen 18 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Regimen 21 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Regimen 24 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Regimen 27 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 21 Months
Study NCT02646488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Post Intervention 24 Months
Study NCT02496156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Medical Decision Making
Description: Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
Study NCT01229202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
Study NCT03530306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS1-PS4
Description: Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
Study NCT03530306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS6-PS10
Description: Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
Study NCT03530306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS7-PS4
Description: Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.